RESUMO
@#ObjectiveTo compare the clinical effect and security of Reparil Gel on osteoarthritis of the knee.Methods60 patients were randomly divided into Reparil Gel group and Fenbid group, who applied Reparil Gel or take Fenbid orally respectively. Western Ontario and McMaster University Osteoarthritis Index (WOMAC) was used to assess patients' pain, joint stiffness and disability of knee on 0 week, 2 week, 6 week after treatment. The side effect was observed.ResultsBoth group showed good clinic effect on 2 weeks (P<0.05)and 6 weeks (P<0.001)after treatment. Significant difference between two group was found 2 weeks after treatment, but there was no difference 6 weeks after. There was no side effect had been observed in Reparil Gel group, while stomachache, nausea or anorexia had been found in 4 case of Fenbid group 2 weeks after, and 8 case of Fenbid group 6 weeks after.ConclusionReparil Gel are same effective as Fenbid, but less side effect happened.
RESUMO
OBJECTIVE:To study the pharmacokinetics and relative bioavailability of ibuprofen sustained release capsules in healthy volunteers for evaluating the bioequi valency .METHODS: 20 healthy volunteers took a single dose(600mg) of ibuprofen sustained release capsules and fenbid capsules(as reference drug) alternatively, then the plasma concentrations of ibuprofen were determined by HPLC.The pharmacokinetic parameters were calculated with 3p87 pharmacokinetic program and the bioequivalence was calculated .RESULTS: The pharmacokinetic parameters of ibuprofen sustained release capsule and fenbid capsule wereT1/2= (2.88+ 0.25)h, (2.91 + 0.33)h;Cmax = (30.66+ 4.21)mg/L, (29.09+3.54)mg/L;Tmax = (4.4 + 0.52)h, (4.3+0.48)h;AUCo-1, = (174.26+13.95)mg/(h . L), (165.80+ 11.89)mg/(h ?L) ;C = (16.25+ 1.47)mg/L, (15.63+1.83) mg/L; Cmin= (1.36 + 0.56) mg/L, (1.24 + 0.46) mg/ L; FI = (1.83 + 0.07), (1.84 + 0.06) .The relative bioavailability of ibuprofen sustained release capsule was( 105.10 + 7.77) % .CONCLUSION: Ibuprofen sustained release capsule and fenbid (reference drug) were bioequivalent.
RESUMO
OBJECTIVE:To observe the clinical efficacy of Cistanche salsa tablets in treating endemic fluorosis. METHODS: A total of 137 cases were enrolled from endemic fluorosis disease-stricken area: 37 were assigned to receive Cistanche salsa tablets(1.2 g) po bid (trial group), and another 100 to receive Fenbid (300 mg) po bid as control for a treatment course of 4 weeks. The outcome measures included the total efficacy, time to take effect, adverse drug reaction and patients’ drug tolerance. RESULTS: In the trial group, the total effective rate was 86.49%, the time to take effect ranged from 7 to 15 days, and the ADR incidence rate was 35.14%, which was of significant difference as compared with control group.The patients in both groups had good drug tolerance. CONCLUSION: Cistanche salsa tablets are effective for endemic fluorosis and superior to Fenbid in efficacy.